ES2187954T3 - Anticuerpos anti-integrina avb3 antagonistas. - Google Patents
Anticuerpos anti-integrina avb3 antagonistas.Info
- Publication number
- ES2187954T3 ES2187954T3 ES98915334T ES98915334T ES2187954T3 ES 2187954 T3 ES2187954 T3 ES 2187954T3 ES 98915334 T ES98915334 T ES 98915334T ES 98915334 T ES98915334 T ES 98915334T ES 2187954 T3 ES2187954 T3 ES 2187954T3
- Authority
- ES
- Spain
- Prior art keywords
- antibodies
- integrine
- avb3
- antagonists
- avb3 antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Anticuerpos monoclonales que reconocen el complejo receptor de integrina alfa{sub,v} beta{sub,3}, pero no se enlazan significativamente a alfa{sub,IIb} beta{sub,IIIa}, inhiben las enfermedades asociadas a la integrina alfa{sub,v} beta{sub,3}.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4385397P | 1997-04-11 | 1997-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2187954T3 true ES2187954T3 (es) | 2003-06-16 |
Family
ID=21929212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98915334T Expired - Lifetime ES2187954T3 (es) | 1997-04-11 | 1998-04-09 | Anticuerpos anti-integrina avb3 antagonistas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6171588B1 (es) |
EP (1) | EP0973550B1 (es) |
JP (1) | JP2001521520A (es) |
AT (1) | ATE225670T1 (es) |
AU (1) | AU6954398A (es) |
CA (1) | CA2284726A1 (es) |
DE (1) | DE69808609T2 (es) |
DK (1) | DK0973550T3 (es) |
ES (1) | ES2187954T3 (es) |
PT (1) | PT973550E (es) |
WO (1) | WO1998046264A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029732A2 (en) | 1997-12-08 | 1999-06-17 | Lexigen Pharmaceuticals Corporation | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
DE69931908T2 (de) * | 1998-04-15 | 2007-01-11 | Lexigen Pharmaceuticals Corp., Lexington | Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor |
US6670321B1 (en) | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
EP1252192B1 (en) | 2000-02-11 | 2006-08-16 | MERCK PATENT GmbH | Enhancing the circulating half-life of antibody-based fusion proteins |
RU2272644C2 (ru) * | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
US7288390B2 (en) * | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
US20030129223A1 (en) * | 2000-10-11 | 2003-07-10 | Targesome, Inc. | Targeted multivalent macromolecules |
US20030082103A1 (en) * | 2000-10-11 | 2003-05-01 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
US20030133972A1 (en) * | 2000-10-11 | 2003-07-17 | Targesome, Inc. | Targeted multivalent macromolecules |
NZ528076A (en) * | 2001-03-02 | 2005-09-30 | Medimmune Inc | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules |
DK1366067T3 (da) * | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
CA2439953A1 (en) * | 2001-03-08 | 2002-09-19 | Mark D. Bednarski | Stabilized therapeutic and imaging agents |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
CN1247258C (zh) * | 2001-04-24 | 2006-03-29 | 默克专利有限公司 | 使用抗血管生成剂和TNFα的联合疗法 |
BR0209177A (pt) * | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
EP1446418B1 (en) * | 2001-10-22 | 2012-05-23 | The Scripps Research Institute | Integrin targeting compounds |
PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
WO2003062198A1 (en) | 2002-01-24 | 2003-07-31 | Barnes Jewish Hospital | Integrin targeted imaging agents |
US20040001835A1 (en) * | 2002-03-04 | 2004-01-01 | Medimmune, Inc. | Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
AU2003213682C1 (en) * | 2002-03-04 | 2008-06-12 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate |
EP1499352A4 (en) | 2002-04-12 | 2006-10-11 | Medimmune Inc | ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES |
AU2003243151A1 (en) * | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
CA2510180C (en) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
SG172479A1 (en) * | 2003-01-22 | 2011-07-28 | Univ Singapore | Molecules, compositions, methods and kits for applications associated with flaviviruses |
US20040176272A1 (en) * | 2003-01-30 | 2004-09-09 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
US7271245B2 (en) * | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
AU2005299355A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
US8637469B2 (en) | 2006-07-11 | 2014-01-28 | Roy C. Levitt | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
DK2068889T3 (da) | 2006-08-10 | 2020-02-03 | Roy C Levitt | Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom |
KR101405440B1 (ko) | 2012-07-31 | 2014-06-20 | 연세대학교 산학협력단 | 인테그린αvβ3에 특이적 압타머 및 이의 용도 |
SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
IL268058B2 (en) | 2017-01-20 | 2023-09-01 | Magenta Therapeutics Inc | Compositions and methods for depleting cd137 plus cells |
KR102101561B1 (ko) * | 2018-07-25 | 2020-04-20 | 가톨릭대학교 산학협력단 | 신생혈관 표적용 조영제 조성물 및 이의 제조방법 |
WO2021015336A1 (ko) * | 2019-07-24 | 2021-01-28 | 가톨릭대학교 산학협력단 | αVβ3 인테그린 표적 단일 도메인 항체 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US4965392A (en) | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
US5591829A (en) | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
US5306620A (en) | 1987-07-08 | 1994-04-26 | The Scripps Research Institute | Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation |
US5130118A (en) | 1987-11-06 | 1992-07-14 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
JPH02502156A (ja) | 1987-11-19 | 1990-07-19 | スクリップス クリニック アンド リサーチ ファウンデーション | 内皮細胞のrgd指向粘着レセプターに対するモノクローナル抗体 |
US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
US5149780A (en) | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
JP3093383B2 (ja) | 1990-11-30 | 2000-10-03 | 塩野義製薬株式会社 | 抗体標識のための放射性ヨウ素化合物 |
WO1993020229A1 (en) | 1992-04-03 | 1993-10-14 | Genentech, Inc. | ANTIBODIES TO ALPHAvBETA3 INTEGRIN |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
DE4338704A1 (de) | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
-
1998
- 1998-04-09 DE DE69808609T patent/DE69808609T2/de not_active Expired - Fee Related
- 1998-04-09 AT AT98915334T patent/ATE225670T1/de not_active IP Right Cessation
- 1998-04-09 WO PCT/US1998/006867 patent/WO1998046264A1/en active IP Right Grant
- 1998-04-09 ES ES98915334T patent/ES2187954T3/es not_active Expired - Lifetime
- 1998-04-09 JP JP54398898A patent/JP2001521520A/ja not_active Abandoned
- 1998-04-09 AU AU69543/98A patent/AU6954398A/en not_active Abandoned
- 1998-04-09 PT PT98915334T patent/PT973550E/pt unknown
- 1998-04-09 DK DK98915334T patent/DK0973550T3/da active
- 1998-04-09 EP EP98915334A patent/EP0973550B1/en not_active Expired - Lifetime
- 1998-04-09 US US09/057,486 patent/US6171588B1/en not_active Expired - Fee Related
- 1998-04-09 CA CA002284726A patent/CA2284726A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE225670T1 (de) | 2002-10-15 |
JP2001521520A (ja) | 2001-11-06 |
EP0973550B1 (en) | 2002-10-09 |
CA2284726A1 (en) | 1998-10-22 |
WO1998046264A1 (en) | 1998-10-22 |
AU6954398A (en) | 1998-11-11 |
EP0973550A1 (en) | 2000-01-26 |
DE69808609D1 (de) | 2002-11-14 |
US6171588B1 (en) | 2001-01-09 |
PT973550E (pt) | 2003-01-31 |
DK0973550T3 (da) | 2003-02-10 |
DE69808609T2 (de) | 2003-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2187954T3 (es) | Anticuerpos anti-integrina avb3 antagonistas. | |
TR199501614A2 (tr) | Anti-alfa integrin monoklonal antikor. | |
RS53984B1 (en) | IP-10 ANTIBODIES AND THEIR USES | |
DE69920897D1 (de) | Monoklonale antikörper mit verringerter immunisierungsfähigkeit | |
DE69637930D1 (de) | Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität | |
AU8316701A (en) | Anti-dual integrin antibodies, compositions, methods and uses | |
NO924279D0 (no) | Lyofilisert, monoklonalt antistoffpreparat | |
ATE318147T1 (de) | Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen | |
GB2383331A (en) | Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof | |
IT1271461B (it) | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. | |
DE69718261T2 (de) | Für staphylococcus aureus spezifischer antikörper und seine verwendung | |
DE69942668D1 (de) | Humanisierter monoklonaler antikörper gegen von-willebrand faktor | |
DE69828154D1 (de) | Anti-alphavbeta3 humanizierte monoklonale antikörper | |
TR199800517A3 (tr) | Hümanize anti-hümen fas antikor. | |
EP0759943A4 (en) | MONOCLONAL ANTIBODIES SPECIFIC TO AN ENDOGLYX-1 ANTIGEN OF VASCULAR ENDOTHELIAL CELLS, THE ANTIGEN ITSELF AND USES THEREOF | |
BR9509902A (pt) | Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante | |
NO20004251D0 (no) | Humaniserte anti-CEA monoklonale antistoffer med høy affinitet | |
DE59608073D1 (de) | Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid | |
ATE293685T1 (de) | Monoklonaler antikörper gegen ratte beta-2- integrin alpha d untereinheit und entsprechendes hybridoma | |
IT8821702A0 (it) | Nuovo anticorpo monoclonale. | |
GB9721432D0 (en) | Improved production of antibodies through the use of antigen antibody complexes | |
DE69020315T2 (de) | Monoklonaler antikörper gegen c-reaktives protein. | |
BR1100555B1 (pt) | anticorpos monoclonais humanizados. | |
TW288020B (en) | Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof | |
ZA986064B (en) | Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and their use. |